Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 232

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1
Chunk 232
---

			(7,184,723
			)

			(6,169,245
			)

			Income tax expense

			800

			800

			Net loss

			(7,185,523
			)

			(6,170,045
			)

			Exchange differences on translation

			76,842

			(27,965
			)

			Net comprehensive loss

			$
			(7,108,681
			)
			 
			$
			(6,198,010
			)

			Weighted average number of common shares

			5,676,708

			3,197,423

			Loss per common share - basic and diluted

			$
			(1.27
			)
			 
			$
			(1.93
			)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

EDESA BIOTECH, INC.

Consolidated Statements of Cash Flows

			Fiscal Year End 

			September 30, 2025

			September 30, 2024

			Cash flows from operating activities:

			Net loss

			$
			(7,185,523
			)
			 
			$
			(6,170,045
			)

			Adjustments for:

			Depreciation and amortization

			119,273

			186,049

			Share-based compensation

			729,642

			537,492

			Gain on loan forgiveness

			-

			(14,766
			)

			Changes in working capital items:

			Accounts and other receivable

			(377,987
			)

			356,339

			Prepaid expenses and other current assets

			107,832

			197,136

			Accounts payable and accrued liabilities

			(715,499
			)

			17,590

			Net cash used in operating activities

			(7,322,262
			)

			(4,890,205
			)

			Cash flows from financing activities:

			Proceeds from issuance of common shares and warrants

			7,717,634

			729,387